ADCT-502

disitamab vedotin · ADC Therapeutics S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ADCT-502, covering 2019-08-28 to 2019-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression [Phase 1]

See pricing